

## Tolebrutinib for Secondary Progressive Multiple Sclerosis

### Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- Multiple Sclerosis Coalition
- Sanofi Pharmaceuticals

We engaged with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having engaged with ICER:

- **Bruce Cohen, MD**, Professor, Davee Department of Neurology and Clinical Neurological Sciences, Northwestern University, Feinberg School of Medicine and Northwestern Medicine
- **Annette Langer-Gould, MD, PhD**, Regional Lead for Clinician and Translational Neuroscience, Kaiser Permanente
- **Ruth Ann Marrie, MD, PhD, FRCPC, FCAHS**, Professor of Medicine, Dalhousie University
- **Kavita Nair, BPharm, MS, PhD, FAAN**, Professor of Neurology and Pharmacy, CU Skaggs School of Pharmacy

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).